Cyclezyme AB (XSAT:CYCLE) Notes Receivable: kr0.00 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSAT:CYCLE Cyclezyme AB XSAT:CYCLE
8 GF Score
Price kr23.90
! 3 Warning Signs
View Full Analysis

What is Cyclezyme AB Notes Receivable?

Cyclezyme AB XSAT:CYCLE -2.05% 8 Notes Receivable is kr0.00 Mil as of Mar. 2026. GuruFocus rates XSAT:CYCLE with a GF Score™ of 8/100. The stock has 3 warning signs investors should review.

Cyclezyme AB's Notes Receivable for the quarter that ended in Mar. 2026 was kr0.00 Mil.

Cyclezyme AB Notes Receivable Historical Data

* Premium members only.

The historical data trend for Cyclezyme AB's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cyclezyme AB Notes Receivable Chart

Cyclezyme AB Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Notes Receivable
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Cyclezyme AB Quarterly Data
Dec20 Dec21 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
XSAT:CYCLE
8GF Score
Cyclezyme AB XSAT:CYCLE
Notes Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cyclezyme AB Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of kr0.00 Mil mean?
Cyclezyme AB (XSAT:CYCLE) has a Notes Receivable of kr0.00 Mil as of Mar. 2026. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Cyclezyme AB and its competitors.
Is Cyclezyme AB's Notes Receivable too high?
Cyclezyme AB's current Notes Receivable is kr0.00 Mil. Overall, Cyclezyme AB has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Cyclezyme AB's Notes Receivable compare to LIN and SHW?
Cyclezyme AB's Notes Receivable of kr0.00 Mil can be compared against companies in the Chemicals industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Chemicals company?
A good Notes Receivable depends on the Chemicals industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Cyclezyme AB and its competitors. Cyclezyme AB's current Notes Receivable is kr0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cyclezyme AB stock overvalued right now?
Cyclezyme AB (XSAT:CYCLE) has a current Notes Receivable of kr0.00 Mil. The current Notes Receivable is kr0.00 Mil. Cyclezyme AB's overall GF Score™ is 8/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For Cyclezyme AB (XSAT:CYCLE), the current Notes Receivable is kr0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cyclezyme AB Business Description

Address Scheelevagen 22, Lund, SWE, 223 63
Cyclezyme AB is a Sweden-based company that has developed an enzymatic platform focused on producing enzymes for green biochemical processes. This platform utilizes biotechnological methods to identify and improve enzymes capable of converting e.g. PET-based plastic materials for new building blocks. The company enables careful experiments and analyses of the behavior of different enzymes in the breakdown of e.g. PET material. The company refines its enzymes and also optimizes the processes for plastic recycling by combining experimental data with data analysis.
8GF Score

Get the complete analysis for XSAT:CYCLE

Notes Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr23.90
Price